Cure My Disease

Don't miss your cure!

 Log in / Sign up

Immune cell levels may predict who will develop severe CMV after transplant

NCT ID NCT07688759

Knowledge-focused Sponsor: The First Affiliated Hospital of Soochow University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This study looks at how well the immune system recovers its ability to fight cytomegalovirus (CMV) in adults who have had a stem cell transplant. Researchers will measure special immune cells called CMV-specific T cells at several points during standard anti-CMV treatment. The goal is to see if low levels of these cells can predict which patients will go on to have severe or hard-to-treat CMV infections. If so, doctors could one day tailor treatment earlier for those at highest risk.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Anti-Cytomegalovirus Therapy (ganciclovir, valganciclovir, foscarnet, maribavir, or other approved anti-CMV medications)
What this could lead to
If successful, this could help doctors identify high-risk patients early and personalize treatment to prevent severe or persistent CMV infection after stem cell transplant.
What could go wrong
This is a small, exploratory study with only 40 participants, so findings may not apply to all patients. It measures immune markers, not direct treatment outcomes, so clinical benefit is uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Aug 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of CMV-seropositive adults (≥18 years of age) who have undergone allogeneic hematopoietic stem cell transplantation (allo-HSCT) and experience their first CMV reactivation after transplantation.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. ≥18 years old and underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT); 2. First CMV reactivation after transplantation; 3. Life expectancy of ≥8 weeks; 4. The participant (or legally acceptable representative, if applicable) has provided written informed consent for the trial. Exclusion Criteria: 1. Recurrence of CMV infection; 2. primary CMV infection in CMV-seronegative recipients (R-); 3. Resistance to known anti-CMV drugs (ganciclovir, valganciclovir, foscarnet, maribavir, etc.); 4. Currently receiving CMV-CTL treatment or lymphocyte infusion.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cytomegalovirus infections are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cytomegalovirus infection immune reconstitution inflammatory syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cytomegalovirus infections Hematopoietic stem cell transplantation (HSCT) Immune reconstitution

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The First Affiliated Hospital of Soochow University

    RECRUITING

    Suzhou, Jiangsu, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.